BERLIN, Jan. 4, 2017 /PRNewswire/ -- Bruker today
announced the acquisition of InVivo Biotech Services GmbH
(www.invivo.de), headquartered in Hennigsdorf, Germany, near Berlin. InVivo Biotech is a molecular biology
contract manufacturing organization (CMO), and a leading provider
of monoclonal antibodies and recombinant proteins. InVivo
Biotech also has significant experience in the development and
production of innovative immunoassay components and research kits.
In 2016, InVivo Biotech had revenues of approximately $5 million. Financial details of the transaction
were not disclosed.
InVivo Biotech is an ISO 9001 certified CMO with over 18 years
of experience in mammalian cell culture and protein
production. The company is providing monoclonal antibodies and
recombinant proteins for its CMO customers, which include
diagnostics companies, major research institutes and
biopharmaceutical companies. Its production covers quantities from
milligrams to grams of purified antibodies, including all
subclasses of IgGs, IgMs and IgEs derived from a collection of more
than 3,000 different hybridoma clones producing human, rat or mouse
monoclonals. InVivo Biotech uses proprietary media for
serum-free cultivation to facilitate highly productive and
cost-effective processes in a high cell density fermentation
process with yields up to 500 mg of antibody per liter of culture
per day.
InVivo Biotech provides a complete range of biotech services,
from cloning, screening and recombinant expression of antigens to
the generation of hybridoma cell lines, and from characterization
of antibodies to final production of the developed monoclonal
antibodies. InVivo Biotech's selection of bacterial, insect
and mammalian protein expression systems provides a wide range of
choices for various applications, taking into account specific CMO
customer needs concerning quantity, bioactivity, structure,
post-translational modifications and purity. Recombinant
proteins are produced via stable or transient
transfection.
InVivo Biotech will continue to operate under its existing name
and management team, and is looking forward to expanding its CMO
partnering business with existing and additional CMO customers.
This major addition in expertise and infrastructure for
consumables development, validation and production also will
support Bruker´s strategy of expanding its microbiology assay menu
for the MALDI Biotyper™ platform. Examples
include Sepsityper™ IVD-CE assays for the fast identification of
bacteria from positive blood cultures, RUO assays for
selective testing of antibiotic
resistance with the MBT-STAR™ assay family,
and work-in-progress syndromic panels for the MALDI
BioTyper as a multiplex PCR reader.
InVivo BioTech's kit development and production
capabilities are expected to shorten time to market for such new
assays. Furthermore, the expertise in monoclonal antibodies opens
new possibilities to combine the specificity of antibody enrichment
with the multi-channel information read-out via the MALDI
Biotyper platform. Antibody enrichment strategies prior to
MALDI Biotyper analysis enable new workflows and
could further shorten microbial cultivation and time to result
(TTR).
These capabilities also support Bruker's activities in
translational pathology research with the MALDI
Tissuetyper™. Enzymes involved in the digestion and
sample preparation of formalin-fixed-paraffin-embedded (FFPE)
tissue are expected to complement the MALDI
Tissuetyper platform. Moreover, monoclonal antibodies
against new protein biomarkers identified in a MALDI
Tissuetyper workflow can be efficiently produced at InVivo
Biotech.
Dr. Wolfgang Weglöhner and Mr.
Siegmund Karasch, the founders and
Managing Directors of InVivo Biotech, commented: "We are very
pleased by the expanded opportunities for our business using the
global commercial infrastructure of Bruker, particularly for
microbiology and pathology. With our molecular biology core
products and CMO services, we anticipate significant growth and
expansion opportunities."
Dr. Wolfgang Pusch, Executive
Vice President at Bruker Daltonics, added: "We are systematically
building up infrastructure to support our rapidly growing
consumables business, especially in the field of microbiology and
to prepare the market development in anatomical and molecular
pathology. Together with our recently announced acquisition in
the field of multiplex PCR-based microbiology testing, the InVivo
Biotech acquisition is expected to greatly accelerate our assay and
consumables business expansion."
About the Bruker MALDI Biotyper
The MALDI Biotyper family of systems enables
molecular identification, and taxonomical classification or
de-replication of microorganisms like bacteria, yeasts and
fungi. Classification and identification of microorganisms is
achieved reliably and quickly using proteomic fingerprinting by
high-throughput MALDI-TOF mass spectrometry. The MALDI
Biotyper uses proteomic fingerprints from bacterial strains
for identification. Published studies have highlighted the greater
accuracy, broader coverage and lower cost offered, as well as
faster time-to-result (TTR).
Applications of the MALDI Biotyper platform
include clinical routine microbial identification, environmental
and pharmaceutical analysis, taxonomical research, food and
consumer product safety and quality control, as well as marine
microbiology. In many European and international laboratories the
MALDI Biotyper has replaced classical biochemical
testing for bacterial identification due to its accuracy, speed,
extensive species coverage, ease of use and cost
effectiveness. Classical biochemical techniques detect
different metabolic properties of microorganisms, can take many
hours or even days for completion, and often lack
specificity.
The robust MALDI Biotyper workflow requires
minimal sample preparation and offers low consumables cost. The
products of the MALDI Biotyper family are available
in a research-use-only (RUO) version, as the U.S. FDA-cleared
MALDI Biotyper CA System, or in an IVD-CE version
according to EU directive EC/98/79. The MALDI
Biotyper also has medical device registrations in numerous
other countries. RUO versions of the MALDI
Biotyper allow selected high-value antimicrobial resistance
tests in translational research, and subtyping
capabilities.
About the Bruker MALDI Tissuetyper
The MALDI Tissuetyper solution, an emerging
technology, enables the use of MALDI-TOF mass spectrometry as a
powerful mass spectrometry imaging (MSI) tool, which is highly
complementary to traditional imaging technologies in histology. The
MALDI Tissuetyper allows pathologists a fast
identification of proteins in tissue samples. In contrast to
traditional histological tissue analysis, the MALDI
Tissuetyper requires neither a molecular probe nor an
antibody. The MALDI Tissuetyper offers multiplex
analysis of multiple potential biomarkers simultaneously in an
untargeted approach. Identification of protein expression profiles,
will lead to the discovery of clinically useful tumor biomarkers
which could be incorporated into future diagnostic and treatment
strategies. MALDI Tissuetyper provides complementary
information to immunohistochemistry (IHC) and in many cases can
differentiate cell populations that cannot easily be differentiated
by IHC. In additional, it might save valuable biopsy material, in
cases where only limited tissue sample is available. The
MALDI Tissuetyper can be used for biomarker discovery
studies, but also for multi-marker tissue-typing and
classification. The MALDI Tissuetyper is currently
available for research use only.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance
scientific research instruments and high-value analytical solutions
enable scientists to explore life and materials at molecular,
cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, in
microscopy, nano-analysis and industrial applications, as well as
in cell biology, preclinical imaging, clinical research,
microbiology and molecular diagnostics. For more information,
please visit www.bruker.com.
Investor
Contact:
Miroslava Minkova
Bruker Head of Investor
Relations
T: +1 (978) 663–3660, ext. 1479
E:
miroslava.minkova@bruker.com
Media
Contact:
Dr. Winfried Busch
Bruker Daltonics Division, Microbiology Business
Tel: +49-421-2205-1242
E: Winfried.Busch@bruker.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bruker-announces-acquisition-of-cmo-invivo-biotech-to-expand-molecular-biology-microbiology-and-pathology-consumables-and-assay-business-300385166.html
SOURCE Bruker Corporation